Lifecore Biomedical (LFCR) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - Lifecore Biomedical reported a quarterly loss of $0.19 per share, which was worse than the Zacks Consensus Estimate of a loss of$0.14, and compared to a loss of $0.05 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of$35.15 million for the quarter ended February 2025, missing the Zacks Consensus Estimate by 3.95% and showing a slight decrease from year-ago revenues of $35.7 million [2] - Lifecore Biomedical shares have declined approximately 3.1$0.07 on revenues of $35.99 million, and for the current fiscal year, it is -$0.91 on revenues of $129.86 million [7] - The estimate revisions trend for Lifecore Biomedical is mixed, resulting in a Zacks Rank 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Lifecore Biomedical belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]